Jeffrey B. Shealy - 29 Sep 2025 Form 4 Insider Report for Palomino Laboratories Inc.

Reporting relationship: President and CEO, Director, 10%+ Owner
Issuer ticker: PALX on OTC
Reported as of: 29 Sep 2025
Net transaction value: +$1,000,000
SEC form: 4
Accepted by SEC: 27 Oct 2025, 16:32:25 UTC
Prior SEC filing: 31 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Shealy

Key filing fact

Jeffrey B. Shealy filed Form 4 for Palomino Laboratories Inc. on 27 Oct 2025.

Key facts

This page summarizes Jeffrey B. Shealy's Form 4 filing for Palomino Laboratories Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Oct 2025, 16:32.

Change

Previous filing in this sequence was filed on 31 Jan 2024.
Current net transaction value: +$1,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700683 Primary reporting owner

Shealy Jeffrey B.

Relationship: President and CEO, Director, 10%+ Owner
Address: 313 BRYANT COURT, PALO ALTO,
Signature: /s/ Jeffrey Shealy
Signature date: 27 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Common Stock

Other

Transaction value
Shares: +3,833,333
Change %: +460%
Price
Shares after: 4,666,666
Date: 29 Sep 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Warrants

Sale

Transaction value: $1,000,000
Shares: +833,333
Change %: +22%
Price: $1.20
Shares after: 4,666,666
Date: 29 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 833,333
Exercise price: $1.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).